Search
Ixmyelocel-T
go.drugbank.com/drugs/DB17601InvestigationalDeveloped by Vericel Corporation, it is being investigated for cardiomyopathy.
Fluorofuranylnorprogesterone F-18
go.drugbank.com/drugs/DB15282InvestigationalFluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography).
Butyrylthiocholine
go.drugbank.com/drugs/DB04250ExperimentalA sulfur-containing analog of butyrylcholine which is hydrolyzed by butyrylcholinesterase to butyrate and thiocholine. It is used as a reagent in the determination of butyrylcholinesterase activity.
Utidelone
go.drugbank.com/drugs/DB17575InvestigationalUtidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering.[A257544,A257549] It is under investigation in clinical trials for various cancers.
mRNA-3705
go.drugbank.com/drugs/DB17668InvestigationalDeveloped by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.[A258843]
RLYB212
go.drugbank.com/drugs/DB17727InvestigationalIt is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.
SAR-439459
go.drugbank.com/drugs/DB17864Investigational[A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
Beractant
go.drugbank.com/drugs/DB06761ApprovedBeractant is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of pho...
Mirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigationalMirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis.
Toripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalOne mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition